New Zealand markets closed

Boston Scientific Corporation (BSX)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
43.45-0.60 (-1.36%)
At close: 04:00PM EST
42.37 -1.08 (-2.49%)
After hours: 07:33PM EST

Boston Scientific Corporation

300 Boston Scientific Way
Marlborough, MA 01752-1234
United States
508 683 4000

IndustryMedical Devices
Full-time employees38,000

Key executives

NameTitlePayExercisedYear born
Mr. Michael F. MahoneyChairman, Pres & CEO2.23MN/A1965
Mr. Daniel J. BrennanExec. VP & CFO1.04M708.41k1966
Mr. Edward F. MackeyExec. VP of Global Operations909.74kN/A1963
Mr. Joseph M. FitzgeraldExec. VP & Pres of Cardiology1.01M2.61M1964
Mr. Jeffrey B. MirvissExec. VP & Pres of Peripheral Interventions875.74k4.15M1966
Mr. Jonathan R MonsonVP, Global Controller & Chief Accounting OfficerN/AN/AN/A
Ms. Jodi Euerle EddySr. VP and Chief Information & Digital OfficerN/AN/A1973
Ms. Susan Vissers LisaVP of Investor RelationsN/AN/AN/A
Mr. Vance R. BrownSr. VP, Gen. Counsel & Corp. Sec.N/AN/AN/A
Ms. Catherine JenningsVP of Global Marketing & New Bus. Devel. of Peripheral InterventionsN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

Corporate governance

Boston Scientific Corporation’s ISS governance QualityScore as of 26 September 2021 is 6. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 7; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.